相似文献
1
Xigris: reducing mortality in adult patients with severe sepsis.
Urol Nurs. 2002 Jun;22(3):200-1.
2
[Xigris and corticoids: what are the perspectives for the patient with severe sepsis?].
Ann Fr Anesth Reanim. 2003 Dec;22 Spec No 1:43-5.
3
[Clinical experience with xigris].
Ann Fr Anesth Reanim. 2003 Dec;22 Spec No 1:46-7.
4
Drug for severe sepsis is withdrawn from market, fails to reduce mortality.
JAMA. 2011 Dec 14;306(22):2439-40. doi: 10.1001/jama.2011.1755.
5
Activated protein C (Xigris): a drug in trouble.
Acta Anaesthesiol Scand. 2007 Feb;51(2):261-2. doi: 10.1111/j.1399-6576.2006.01215.x.
6
Benefit of recombinant human activated protein C beyond 28-day mortality: there is more to life than death.
Crit Care Med. 2003 Mar;31(3):984-5. doi: 10.1097/01.CCM.0000055386.01914.0C.
7
Activated protein C (Xigris) treatment in sepsis: a drug in trouble.
Acta Anaesthesiol Scand. 2006 Sep;50(8):907-10. doi: 10.1111/j.1399-6576.2006.01086.x.
8
The Sepsis Saga: Consensus to Xigris.
Air Med J. 2016 Jul-Aug;35(4):194-6. doi: 10.1016/j.amj.2016.04.010. Epub 2016 Jun 3.
9
Drotrecogin alfa (activated) in severe sepsis.
N Engl J Med. 2006 Jan 5;354(1):94-6; author reply 94-6.
10
[Surgical patients with severe sepsis: first results of the PROWESS study. Demographic data].
Ann Fr Anesth Reanim. 2003 Dec;22 Spec No 1:38-9.
Zotero 插件